<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978753</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO 1063</org_study_id>
    <nct_id>NCT04978753</nct_id>
  </id_info>
  <brief_title>the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase II Clinical Study of the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung cancer-----a Prospective, Single-arm Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li-kun Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subject population：Patients with brain metastases from EGFR mutation-positive non-small cell&#xD;
      lung cancer who have not received systemic treatment.&#xD;
&#xD;
      Experimental design: Single-center, single-arm phase II clinical trial. Purpose: Efficacy and&#xD;
      safety of Anlotinib combined with Almonertinib in the treatment of patients with brain&#xD;
      metastases from EGFR mutation-positive non-small cell lung cancer.&#xD;
&#xD;
      treatment plan: 1). Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA&lt;1.6 m2), once a day&#xD;
      orally, taking two weeks and stopping for one week; 2). Almonertinib: 110mg, orally once a&#xD;
      day; primary endpoint: Intracranial progression-free survival (iPFS); secondary endpoint:&#xD;
      Objective intracranial response rate (iORR=iCR+iPR), intracranial disease control rate&#xD;
      (iDCR=iCR+iPR+i SD), overall progression-free survival (PFS), overall survival (OS), quality&#xD;
      of life score.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iPFS</measure>
    <time_frame>10-25months</time_frame>
    <description>Intracranial progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>iORR</measure>
    <time_frame>10-25momths</time_frame>
    <description>Objective intracranial response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iDCR</measure>
    <time_frame>10-25months</time_frame>
    <description>intracranial disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>10-25momths</time_frame>
    <description>overall progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>10-40months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib (12mg/time (BSA≥1.6 m2) or 10mg/time (BSA&lt;1.6 m2), once a day orally, taking two weeks and stopping for one week) combine with Almonertinib (110mg, orally once a day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA&lt;1.6 m2), once a day orally, taking two weeks and stopping for one week;&#xD;
Almonertinib: 110mg, orally once a day;</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>almonertinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) 18-75 years old, ECOG PS score: 0-2 points; and there is no worsening of the disease&#xD;
        within 2 weeks before enrollment, and the expected survival time is more than 3 months; 2)&#xD;
        Advanced non-small cell lung cancer diagnosed by histology or cytology; 3) Baseline&#xD;
        inspection confirms that the tumor has EGFR sensitive mutations (first-generation or&#xD;
        second-generation sequencing, the detection can accept the following two types of tissue:&#xD;
        archive tumor tissue; tumor tissue freshly collected during the screening period); 4)&#xD;
        Asymptomatic or mildly symptomatic brain metastases (headache, nausea or epilepsy and other&#xD;
        symptoms can be controlled with a fixed dose of mannitol/dexamethasone/pain&#xD;
        relievers/antiepileptic drugs for more than 3 days); 5) MRI confirmed tumor metastasis to&#xD;
        brain parenchyma, brain lesions ≥3; or patients with 1-2 brain lesions but not suitable for&#xD;
        local treatment or refusal to local treatment. The brain lesions must have at least one&#xD;
        measurable lesion with a diameter of ≥5mm; 6) Have not received systemic treatment after&#xD;
        brain metastasis (the treatment adopted by neoadjuvant treatment is not included in the&#xD;
        treatment plan, and the recurrence within 6 months after the end of the adjuvant treatment,&#xD;
        the adjuvant treatment part is defined as first-line treatment, and cannot be included in&#xD;
        this study; If the recurrence is more than 6 months, adjuvant treatment will not be&#xD;
        included in the treatment plan); 7) The main organs are functioning normally, that is, they&#xD;
        meet the following standards:&#xD;
&#xD;
          1. The standard of routine blood examination must meet (no blood transfusion within 14&#xD;
             days, no use of granulocyte colony stimulating factor and other hematopoietic&#xD;
             stimulating factors):&#xD;
&#xD;
          2. HB≥90g/L;&#xD;
&#xD;
          3. ANC≥1.5×109/L;&#xD;
&#xD;
          4. PLT ≥80×109/L;&#xD;
&#xD;
          5. The biochemical inspection shall meet the following standards:&#xD;
&#xD;
          6. TBIL &lt;1.5 times the upper limit of normal (ULN);&#xD;
&#xD;
          7. ALT and AST&lt;2.5 ULN; if there is liver metastasis, ALT and AST&lt;5 ULN;&#xD;
&#xD;
          8. Cr≤1.25 ULN or creatinine clearance (CCr) ≥45ml/min (Cockcroft-Gaulat formula);&#xD;
&#xD;
          9. Urine protein &lt;2+ (when the baseline urine protein is 2+, a 24-hour urine protein&#xD;
             quantification should be performed, and it can only be selected when it is ≤1g);&#xD;
&#xD;
         10. The international normalized ratio of blood coagulation (INR) ≤ 1.5 and APTT ≤ 1.5&#xD;
             ULN;&#xD;
&#xD;
         11. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit&#xD;
             of normal value (50%); 8) Women of childbearing age should agree to use contraceptive&#xD;
             measures (such as intrauterine devices, contraceptives or condoms) during the study&#xD;
             period and within 6 months after the end of the study; serum or urine pregnancy test&#xD;
             is negative within 7 days before study entry , And must be non-lactating patients; men&#xD;
             should agree to patients who must use contraception during the study period and within&#xD;
             6 months after the end of the study period.&#xD;
&#xD;
        9) The patients voluntarily joined the study, signed an informed consent form, and had good&#xD;
        compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Small cell lung cancer (including lung cancer mixed with small cell carcinoma and&#xD;
        non-small cell carcinoma); 2) Brain metastases accompanied by active bleeding; 3) Those who&#xD;
        have previously used anti-tumor angiogenesis drugs (such as bevacizumab, endurance,&#xD;
        anlotinib, etc.) treatment failure; 4) At the beginning of the study treatment, there was&#xD;
        an unhealed toxic reaction of grade ≥2 (NCI-CTC AE4.03) related to the previous treatment:&#xD;
        (except for hair loss and grade 2 neuropathy caused by platinum drugs) 5) Those who have a&#xD;
        variety of factors that affect oral medications (such as uncontrollable nausea and&#xD;
        vomiting, inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal&#xD;
        obstruction, etc.); 6) Local radiotherapy to relieve the disease within 14 days before the&#xD;
        first administration of the study treatment; radiotherapy or extensive radiotherapy for&#xD;
        more than 30% of the bone marrow area within 4 weeks before the first administration (for&#xD;
        palliative treatment of non-brain metastases such as bone metastases) Except for&#xD;
        radiotherapy); 7) Patients with any severe and/uncontrolled diseases, including:&#xD;
&#xD;
          1. Patients with unsatisfactory blood pressure control (systolic blood pressure ≥140 mmHg&#xD;
             or diastolic blood pressure ≥90 mmHg);&#xD;
&#xD;
          2. Meet any of the following cardiac standards: In the resting state, the average&#xD;
             corrected QT interval (QTcF) obtained from 3 ECG examinations is ≥470 msec (Fredericia&#xD;
             formula is used, see Appendix 4 for details). Various clinically significant heart&#xD;
             rhythm, conduction, and resting ECG morphological abnormalities, such as complete left&#xD;
             bundle branch block, third-degree block, second-degree block, and PR interval ≥250&#xD;
             msec. Various factors that may increase the risk of QTc prolongation or the risk of&#xD;
             arrhythmia events, such as cardiac insufficiency according to NYHA standards III to&#xD;
             IV; heart failure; hypokalemia; congenital long QT syndrome; family history with long&#xD;
             first-degree relatives QT syndrome or sudden death of unknown cause under 40 years of&#xD;
             age; various combined medications that may prolong the QT interval.&#xD;
&#xD;
          3. Active or uncontrolled serious infection;&#xD;
&#xD;
          4. Liver diseases such as cirrhosis, decompensated liver disease, chronic active&#xD;
             hepatitis;&#xD;
&#xD;
          5. Poor diabetes control (fasting blood glucose (FBG)&gt; 10mmol/L);&#xD;
&#xD;
          6. Urine routine shows that urine protein is ≥++, and the 24-hour urine protein&#xD;
             quantification is confirmed to be greater than 1.0 g; 8) Long-term unhealed wounds or&#xD;
             fractures; 9) Pulmonary hemorrhage with NCI CTC AE grade&gt; Grade 1 occurred within 4&#xD;
             weeks before enrollment; other parts of bleeding with NCI CTC AE grade&gt; Grade 2&#xD;
             occurred within 4 weeks before enrollment; hemorrhage tendency (such as active peptic&#xD;
             ulcer) Or patients who are receiving thrombolytic or anticoagulant therapy such as&#xD;
             warfarin, heparin or their analogues; 10) Those who have had arterial/venous&#xD;
             thrombotic events within 12 months before enrollment, such as cerebrovascular&#xD;
             accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral&#xD;
             infarction), deep vein thrombosis and pulmonary embolism; 11) Clinically significant&#xD;
             hemoptysis (more than 50ml of hemoptysis per day) occurred within 3 months before&#xD;
             enrollment; or significant clinically significant bleeding symptoms or clear bleeding&#xD;
             tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult&#xD;
             blood at baseline ++ and above, or suffer from vasculitis, etc.; 12) Have the&#xD;
             following past history: interstitial lung disease, drug-induced interstitial lung&#xD;
             disease, radiation pneumonitis requiring steroid therapy, clinically active&#xD;
             interstitial lung disease; 13) People who have a history of psychotropic drug abuse&#xD;
             and cannot be quit or have mental disorders; 14) Respiratory syndrome (≥CTC AE grade 2&#xD;
             dyspnea), severe pleural fluid, ascites, and pericardial effusion; 15) A history of&#xD;
             immunodeficiency, including HIV positive or other acquired or congenital&#xD;
             immunodeficiency diseases, or a history of organ transplantation; active infection,&#xD;
             such as HBV (HBV DNA copy number&gt; 103/ml), HCV, HIV, etc.; 16) According to the&#xD;
             judgment of the investigator, those with concomitant diseases that seriously endanger&#xD;
             the safety of the patient or affect the completion of the study.&#xD;
&#xD;
        17) The patient has active ingredients or inactive excipients, chemical structure and&#xD;
        AZD9291 (and/or anlotinib) to AZD9291 (and/or anlotinib) A history of hypersensitivity to&#xD;
        drugs similar to / or Anlotinib or AZD9291 (and/or Anlotinib).&#xD;
&#xD;
        18) Men or women who have fertility but have not taken effective contraceptive measures,&#xD;
        women are pregnant or breastfeeding, or have a positive pregnancy test (urine or serum)&#xD;
        before entering the study.&#xD;
&#xD;
        19) Because the patient is unwilling to comply with the research procedures, restrictions&#xD;
        and requirements, the researcher determines that the patient should not participate in the&#xD;
        research.&#xD;
&#xD;
        20) Allogeneic bone marrow transplantation has been performed. 21) Any serious or&#xD;
        uncontrolled eye disease may increase the safety risk of the patient according to the&#xD;
        judgment of the investigator; 22) In the 120 days before the collection of genetic samples,&#xD;
        whole blood without leukocytes was transfused; 23) The patient has other coexisting&#xD;
        malignant tumors or has been diagnosed with other malignant tumors in the last 5 years,&#xD;
        except for basal cell carcinoma, cervical or squamous cell skin cancer in situ, and&#xD;
        papillary thyroid carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Likun Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Likun Chen</last_name>
    <phone>02087343410</phone>
    <email>chenlk@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowen Guo</last_name>
      <phone>+8615013080864</phone>
      <email>guoxw@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li-kun Chen</investigator_full_name>
    <investigator_title>sun yat-sen university cancer center</investigator_title>
  </responsible_party>
  <keyword>EGFR mutation</keyword>
  <keyword>NSCLC</keyword>
  <keyword>brain metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

